"CD52 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A small GPI-linked glycoprotein expressed on the surface of normal and malignant B-CELLS; T-CELLS; MONOCYTES; MACROPHAGES; NK CELLS; and GRANULOCYTES. It is expressed densely and without modulation in many malignant T-cell neoplasms and therefore a target for antibody therapies (e.g., ALEMTUZUMAB).
| Descriptor ID |
D000074301
|
| MeSH Number(s) |
D12.776.395.550.448.190 D12.776.543.484.500.190 D12.776.543.550.418.190 D23.050.285.022 D23.101.100.943
|
| Concept/Terms |
CD52 Antigen- CD52 Antigen
- CDw52 Antigen
- Campath-1 Antigen
- Campath 1 Antigen
- Campath-1H Antigen
- Campath 1H Antigen
- Lymphocyte Antigen CDw52
- CDw52, Lymphocyte Antigen
- Lymphocyte Antigen CD52
- CD52, Lymphocyte Antigen
- Campath-1 Receptor
- Campath 1 Receptor
- HLA-Bw52 Antigen
- HLA Bw52 Antigen
- HLA-Bw52
- HLA Bw52
- Cambridge Pathology 1 Antigen
- CD52 Protein
|
Below are MeSH descriptors whose meaning is more general than "CD52 Antigen".
Below are MeSH descriptors whose meaning is more specific than "CD52 Antigen".
This graph shows the total number of publications written about "CD52 Antigen" by people in this website by year, and whether "CD52 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 4 | 4 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 5 | 5 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "CD52 Antigen" by people in Profiles.
-
Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol. 2010 Feb; 148(3):386-93.
-
CD52 antigen may be a therapeutic target for eosinophilic rhinosinusitis. Ann Clin Lab Sci. 2007; 37(2):148-51.
-
Alemtuzumab in CLL and other lymphoid neoplasms. Cancer Invest. 2006 Nov; 24(7):718-25.
-
Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer. 2006 Jun 15; 106(12):2645-51.
-
Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenstr?m macroglobulinemia. Am J Clin Pathol. 2005 Sep; 124(3):414-20.
-
CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors. Bone Marrow Transplant. 2005 Jun; 35(12):1127-32.
-
Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2005 Mar; 44(3):251-4.
-
Identification of LKLF-regulated genes in quiescent CD4+ T lymphocytes. Mol Immunol. 2005 Mar; 42(5):627-41.
-
Alemtuzumab. Expert Rev Anticancer Ther. 2005 Feb; 5(1):39-51.
-
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer. 2004 Sep 01; 101(5):999-1008.